DelveInsight’s “Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder, historical and forecasted epidemiology as well as the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Get a Free sample for the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Some of the key facts of the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Report:
• The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market is projected to experience a rise at a significant CAGR during the forecast period from 2024 to 2034. The growth in market revenue is primarily driven by increasing awareness and diagnosis of the disorder, advancements in genetic testing technologies, and the development of new and innovative therapies.
• In May 2026, Viralgen forged a strategic manufacturing partnership with Elaaj Bio to advance a novel gene therapy program targeting CDKL5 Deficiency Disorder (CDD). Under the agreement, Viralgen will deploy its world-class current Good Manufacturing Practice (cGMP) suspension-based AAV platform to scale the production of Elaaj Bio’s innovative adeno-associated virus vector pipeline, accelerating preclinical development and streamlining the path toward upcoming clinical trials.
• In March 2022, the U.S. FDA approved ZTALMY (ganaxolone) as the first treatment specifically approved for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD) in people 2 years of age and older. The approval was followed by European approval in 2023, with ZTALMY’s efficacy demonstrated in the Marigold trial, which revealed a notable reduction in major motor seizure frequency compared to placebo.
• According to the estimates, the total diagnosed prevalent cases of CDKL5 Deficiency Disorder in the seven major markets were approximately 4,300 cases in 2023. The cases in the 7MM are expected to increase during the forecast period, i.e., 2024-2034.
• The United States contributed to the largest diagnosed prevalent population of CDD, acquiring approximately 37% of the 7MM in 2023, with around 1,846 cases. EU4 and the UK accounted for around 48%, and Japan accounted for approximately 15% of the total population share.
• Among EU4 countries, Germany accounted for the largest number of prevalent CDD cases (2,772 cases), followed by Italy (1,809 cases), whereas Spain accounted for the lowest number of cases (890 cases) in 2023.
• The study conducted in the US indicates that CDKL5 deficiency disorder primarily affects females, who constitute about 90% of cases, with approximately 86% female and 14% male diagnosed prevalent cases estimated in the US in 2023. However, there has been an increase in diagnoses among males, who display symptoms similar to those seen in females.
• Clinical characteristics of CDKL5 Deficiency Disorder are diverse, with notable distribution rates: epileptic spasms (12.1%), hypsarrhythmia (7.0%), cortical visual impairment (11.2%), hand stereotypies (11.9%), gastrointestinal symptoms (12.9%), constipation (10.6%), reflux (9.6%), and sleep difficulties (12.7%). These percentages underscore the multifaceted and widespread impact of CDKL5 Deficiency Disorder on patients.
• In 2023, it was estimated that there were approximately 491 cases of Epileptic Spasms, 285 cases of Hypsarrhythmia, 455 cases of Cortical Visual Impairment, 485 cases of Hand Stereotypies, 524 cases of Gastrointestinal Symptoms, 430 cases of Constipation, 388 cases of Reflux, and 515 cases of Sleep difficulties diagnosed prevalent cases of CDD in Japan.
• Fenfluramine, an investigational serotonin-releasing agent being developed by UCB, is currently advancing through Phase III clinical trials for CDKL5 Deficiency Disorder. Topline results from these trials are anticipated by the second half of 2024, offering a promising glimpse into the drug’s efficacy and its potential to address a critical unmet need in managing this severe neurological disorder.
• UX055, a gene therapy being developed by Ultragenyx Pharmaceutical Inc., represents a promising frontier in the treatment of CDKL5 Deficiency Disorder. Currently in preclinical development, this investigational gene therapy employs an Adeno-Associated Vector Serotype 9 (AAV9) to deliver a functional copy of the human CDKL5 gene directly to the brain.
• Key Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Companies: Marinus Pharmaceuticals, Inc., UCB, Ultragenyx Pharmaceutical Inc., Viralgen, Elaaj Bio, and others
• Key Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Therapies: ZTALMY (ganaxolone), Fenfluramine, UX055, and others
• The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market is expected to surge due to the disease’s increasing prevalence, growing awareness, and advancements in genetic testing technologies during the forecast period. Furthermore, launching various pipeline products, including gene therapies and novel pharmacological agents, will significantly revolutionize the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market dynamics.
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Overview
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder or CDD is a remarkably rare and complex developmental epileptic encephalopathy (DEE) resulting from genetic mutations within the CDKL5 gene, located on the X chromosome. This genetic condition is categorized as a DEE due to the fact that the mutations in the CDKL5 gene are responsible for both the onset of epileptic seizures and the severe developmental impairment experienced by affected individuals. CDKL5 was previously known as serine/threonine-protein kinase 9 (STK9), and it wasn’t until 2004 that researchers first identified its association with disease.
CDD is characterized by the profound impact it has on the affected individual’s neurological and cognitive development. Seizures in CDD often manifest within the first few months of life and can be challenging to manage. They typically require a multifaceted approach involving various antiepileptic medications and therapies. The mutations in the CDKL5 gene disrupt the normal function of the CDKL5 protein, which plays a crucial role in regulating the development and function of neurons. This disruption in neuronal development leads to severe developmental delays, intellectual disabilities, and motor impairments, making CDD a highly debilitating condition.
To Know in detail about the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Forecast
https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Segmentation:
The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalent cases of CDKL5 Deficiency Disorder in the 7MM
• Diagnosed Prevalent cases of CDKL5 Deficiency Disorder in the 7MM
• Gender-specific Prevalence of CDKL5 Deficiency Disorder in the 7MM
• Clinical Manifestation Specific Prevalent cases of CDKL5 Deficiency Disorder in the 7MM
• Treated cases of CDKL5 Deficiency Disorder in the 7MM
Download the report to understand which factors are driving Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology trends @ Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Forecast
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market or expected to get launched during the study period. The analysis covers Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Therapies and Key Companies
• ZTALMY (ganaxolone): Marinus Pharmaceuticals, Inc. – ZTALMY is the first treatment approved specifically for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD) in people 2 years of age and older. It functions by providing anti-seizure and anti-anxiety effects through its action on both synaptic and extrasynaptic GABAA receptors. Approved in March 2022 in the US and in 2023 in Europe.
• Fenfluramine: UCB – An investigational serotonin-releasing agent currently in Phase III clinical trials that uniquely stimulates multiple 5-HT receptor subtypes through the release of serotonin, and also interacts with the sigma-1 receptor. Topline results are anticipated by the second half of 2024.
• UX055: Ultragenyx Pharmaceutical Inc. – An investigational gene therapy in preclinical development employing an Adeno-Associated Vector Serotype 9 (AAV9) to deliver a functional copy of the human CDKL5 gene directly to the brain via injection into the cerebrospinal fluid.
Discover more about therapies set to grab major Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market share @ Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment Landscape
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Drivers
• Increasing awareness and diagnosis: Growing recognition of CDKL5 Deficiency Disorder among healthcare providers and the general public is leading to earlier and more accurate diagnoses, expanding the addressable patient population.
• Advancements in genetic testing technologies: Improvements in genetic testing methods, including next-generation sequencing and whole-exome sequencing, are facilitating faster and more accurate identification of CDKL5 mutations, enabling timely intervention and treatment.
• Development of innovative therapies: The emergence of novel therapeutic approaches, including gene therapy (UX055), targeted pharmacological agents (Fenfluramine), and disease-modifying treatments, is creating significant market opportunities and addressing previously unmet medical needs.
• Growing research funding and initiatives: Increasing support from research funding organizations and patient advocacy groups is driving the development of new treatment options and improving patient care.
• First approved therapy for CDD: The FDA approval of ZTALMY in 2022 and subsequent European approval in 2023 established a dedicated treatment pathway for CDD, setting a precedent for future therapeutic development.
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Barriers
• Lack of validated clinical outcome measures: The absence of well-established and validated clinical outcome measures for trial assessment hampers the development of effective therapies and complicates the evaluation of treatment efficacy.
• Limited awareness among healthcare providers: CDKL5 Deficiency Disorder’s rarity contributes to limited awareness among healthcare professionals, leading to potential delays in diagnosis and treatment initiation.
• Intractable seizures: Seizures associated with CDKL5 Deficiency Disorder often resist conventional antiepileptic medications, underscoring the need for more effective, targeted treatment options.
• High cost of therapies: The high cost of advanced therapies and specialized treatments presents a significant economic burden on patients and healthcare systems, potentially limiting patient access to optimal care.
• Complex symptomatology: The multifaceted nature of CDD, encompassing both neurological and developmental symptoms, requires a comprehensive, multidisciplinary treatment approach that can be challenging to implement consistently.
Scope of the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
• Key Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Companies: Marinus Pharmaceuticals, Inc., UCB, Ultragenyx Pharmaceutical Inc., Viralgen, Elaaj Bio, and others
• Key Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Therapies: ZTALMY (ganaxolone), Fenfluramine, UX055, and others
• Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Therapeutic Assessment: Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder current marketed and emerging therapies
• Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Dynamics: Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Unmet Needs, KOL’s views, Analyst’s views, Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Access and Reimbursement
Key Highlights of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder:
• CDD is a rare genetic condition categorized as a developmental epileptic encephalopathy (DEE) resulting from mutations in the CDKL5 gene, located on the X chromosome, essential for brain and neuron development.
• Identified in 2004, CDD has significant impacts on affected individuals and their families.
• The treatment market of CDD currently lacks disease-modifying approved therapy specific to CDD treatment, with ZTALMY being the first therapy approved specifically for seizures associated with CDD.
• The existing treatment includes symptomatic and supportive care, with a multidisciplinary team approach vital to delivering appropriate care.
• Early interventions include physical therapy, occupational therapy, speech and augmentative communication therapy, while seizure treatment includes Antiepileptic Drugs (AEDs), Steroid Treatment, Ketogenic Diet, Neurosurgery, and Vagus Nerve Stimulation (VNS).
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports clients by providing comprehensive research solutions with precision and speed, offering services including end-to-end market research reports, customized research, competitive intelligence, and business consulting.
Contact Us
Kanishk
